Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randall Randazzo

Urology Schaumburg, IL Medical Doctor

NPI 1801897889 CMS profile 217444

806 E Woodfield Rd, Schaumburg, IL 60173

Open in the dashboard

General payments

$1,878

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randall Randazzo of Schaumburg, IL is reported in the CMS Open Payments database as having received $1,878 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $464 2
2024 General $55 2
2023 General $28 1
2021 General $203 8
2020 General $458 19
2019 General $671 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randall Randazzo
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Randall Randazzo were reported at $464. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Randall Randazzo Urology median Middle half National median
2019 $671 $480 $147–$1,201 $163
2020 $458 $246 $87–$645 $114
2021 $203 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $28 $560 $168–$1,461 $160
2024 $55 $563 $170–$1,464 $164
2025 $464 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $496 16 payments
  2. Boston Scientific Corporation $464 2 payments
  3. Olympus America Inc. $260 9 payments
  4. AbbVie, Inc. $173 8 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $110 7 payments
  6. Pfizer Inc. $100 6 payments
  7. AngioDynamics, Inc. $83 3 payments
  8. Janssen Biotech, Inc. $78 4 payments
  9. Merck Sharp & Dohme Corporation $31 1 payment
  10. Metuchen Pharmaceuticals $24 1 payment
  11. Other $60 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,528 57 payments
  2. Travel and Lodging $239 1 payment
  3. Education $111 2 payments
Products named General payments · program years 2019–2025
  1. Lumenis Pulse 120H $464 2 payments
  2. XTANDI $260 13 payments
  3. UGN Laser Capital $159 2 payments
  4. Xofigo $110 7 payments
  5. LUPRON DEPOT Endocrinology $93 4 payments
  6. Nubeqa $90 6 payments
  7. NANOKNIFE $83 3 payments
  8. MYRBETRIQ $82 6 payments
  9. LUPRON DEPOT Endocrinology $80 4 payments
  10. ERLEADA $78 4 payments
  11. Other $214 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,918

Median for Urology: 1,053

Drug cost

$128,361

Median for Urology: $101,464

Branded share of claims

12.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 76 $75,528
Tamsulosin Hcl Generic 629 $12,559
Potassium Citrate Er Potassium Citrate Brand 105 $11,267
Bethanechol Chloride Generic 113 $7,113
Finasteride Generic 482 $6,120
Methenamine Hippurate Generic 49 $5,355
Estradiol Generic 40 $2,963
Bicalutamide Generic 60 $1,875
Alfuzosin Hcl Er Alfuzosin Hcl Brand 66 $1,308
Allopurinol Generic 89 $1,042

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$145,235

Of which drugs: $8,513

Medicare patients

533

Average age 78

Services billed

2,542

106 women, 427 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 47%
Diabetes 40%
Cancer 39%
Chronic kidney disease 37%
Atrial fibrillation 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record